Home » Stocks » Interpace Biosciences

Interpace Biosciences, Inc. (IDXG)

Stock Price: $3.35 USD -0.64 (-16.04%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 13.54M
Revenue (ttm) 26.45M
Net Income (ttm) -41.95M
Shares Out 4.04M
EPS (ttm) -8.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $3.35
Previous Close $3.99
Change ($) -0.64
Change (%) -16.04%
Day's Open 3.75
Day's Range 3.22 - 3.81
Day's Volume 513,154
52-Week Range 2.57 - 11.00

More Stats

Market Cap 13.54M
Enterprise Value 5.77M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 4.04M
Float 4.00M
EPS (basic) -8.53
EPS (diluted) -8.50
FCF / Share -4.67
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 249,202
Short Ratio 1.54
Short % of Float 6.23%
Beta 1.52
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.51
PB Ratio 2.37
Revenue 26.45M
Operating Income -29.96M
Net Income -41.95M
Free Cash Flow -18.84M
Net Cash 7.77M
Net Cash / Share 1.92
Gross Margin 30.97%
Operating Margin -113.28%
Profit Margin -126.00%
FCF Margin -71.25%
ROA -28.06%
ROE -74.94%
ROIC -291.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(246.87% upside)
Current: $3.35
Target: 11.62
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth9.97%37.74%21.49%38.73%539.89%-98.99%15.47%-19.32%16.87%-
Gross Profit8.1911.708.546.442.520.2123.5126.8632.4726.55
Operating Income-26.91-10.93-11.90-18.30-46.53-17.83-1.44-25.23-1.81-6.90
Net Income-27.16-12.19-12.22-8.33-11.36-16.07-4.57-25.53-11.91-6.81
Shares Outstanding3.752.821.580.
Earnings Per Share-7.25-4.33-7.70-45.90-73.40-108.00-31.00-175.00-83.00-48.00
Operating Cash Flow-18.96-8.67-15.26-7.61-19.84-16.38-3.51-10.291.9916.35
Capital Expenditures-0.12-0.45-0.03--0.35-2.85-1.82-1.11-0.34-2.13
Free Cash Flow-19.08-9.12-15.29-7.61-20.20-19.23-5.33-11.401.6414.22
Cash & Equivalents2.326.0715.200.608.4223.2245.7452.8864.4662.86
Total Debt5.59--7.918.4027.15----
Net Cash / Debt-3.276.0715.20-7.310.02-3.9445.7452.8864.4662.86
Book Value13.0332.9439.876.5313.0420.1232.4835.6359.5269.51
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Interpace Biosciences, Inc.
Country United States
Employees 176
CEO Jack E. Stover

Stock Information

Ticker Symbol IDXG
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: IDXG
IPO Date May 20, 1998


Interpace Biosciences provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.